Locally Delivered 1% Metformin Gel in Peri-implantitis

King Saud University

Status and phase: Completed; Phase 4

Conditions: Peri-Implantitis

Treatments: Drug: 1% local metformin gel; Procedure: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03312582

FR-17-75

Details and patient eligibility

About

This study evaluates the efficacy of 1% local metformin gel in deep periimplant pockets of type 2 diabetes mellitus patients. Half of the participants will receive 1% metformin gel with manual debridement while the other half will receive a placebo with manual debridement.

Full description

Metformin is an oral hypoglycemic drug categorized under biguanide and are considered the most efficient agents widely used in the treatment of type 2 diabetes mellitus.The general clinical benefits observed in therapy with MF seem to be greater than expected. They induce osteoblast cells to promote early bone formation through AMP kinase (AMPK) activity. Moreover, in a recent in vitro study, MF facilitated in the proliferation of MG63 osteoblast like cells. Thus, their action in stimulating bone formation has justified their use in the treatment of perimplantitis.

Enrollment: 46 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Type 2 diabetes mellitus patients.
• Patients with peri-implantitis

Exclusion criteria

• History of any other systemic diseases
• Cigarette smokers
• Smokeless tobacco users
• Patients who underwent scaling in the last 1 year
• Patients who took antibiotics in tje past 6 months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

46 participants in 2 patient groups, including a placebo group

Manual debridement and 1% metformin gel

Experimental group

Treatment:

Drug: 1% local metformin gel

Manual debridement and placebo

Placebo Comparator group

Treatment:

Procedure: Placebo